论文部分内容阅读
目的探究来氟米特联合厄贝沙坦治疗狼疮性肾炎(LN)疗效及对肾功能的影响。方法 82例LN患者依照建档顺序分组,各41例。两组均给予泼尼松治疗,于此基础上对照组给予环磷酰胺联合厄贝沙坦治疗,观察组予以来氟米特联合厄贝沙坦治疗,疗程6个月。对比两组治疗前后血肌酐(Scr)、尿素氮(BUN)、红细胞沉降率(ESR)、补体C3水平,评估疗效,统计不良反应。结果治疗前两组Scr、BUN、ESR、补体C3水平无差异(P>0.05);治疗后观察组Scr、BUN、ESR水平均低于对照组,补体C3水平高于对照组(P<0.05);观察组总有效率90.24%(37/41)高于对照组70.73%(29/41)(P<0.05),不良反应发生率9.76%(4/41)低于对照组26.83%(11/41)(P<0.05)。结论来氟米特与厄贝沙坦治疗LN患者效果显著,可明显改善肾功能,且不良反应少。
Objective To investigate the effect of leflunomide combined with irbesartan in the treatment of lupus nephritis (LN) and its effect on renal function. Methods 82 cases of LN patients were grouped according to the order of filing, each 41 cases. Both groups were given prednisone treatment, on the basis of the control group given cyclophosphamide combined irbesartan treatment, the observation group was treated with leflunomide combined irbesartan for 6 months. The levels of serum creatinine (Scr), blood urea nitrogen (BUN), erythrocyte sedimentation rate (ESR) and complement C3 were compared before and after treatment to evaluate the curative effect and to count the adverse reactions. Results The levels of Scr, BUN, ESR and complement C3 had no significant difference before treatment (P> 0.05). After treatment, the levels of Scr, BUN and ESR in the observation group were lower than those in the control group and the level of complement C3 was higher than that in the control group (P <0.05) . The total effective rate in the observation group was 90.24% (37/41) higher than that in the control group (70.73%, 29/41), and the adverse reaction rate was 9.76% (4/41) lower than that in the control group (26.83% 41) (P <0.05). Conclusion Leflunomide and irbesartan treatment of LN patients with significant effect, can significantly improve renal function, and less adverse reactions.